{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:44:37Z","timestamp":1784036677953,"version":"3.55.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jscai.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Society for Cardiovascular Angiography & Interventions"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jscai.2023.100607","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:49:32Z","timestamp":1678121372000},"page":"100607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-0702","authenticated-orcid":false,"given":"Alexander","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Gitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3664-4102","authenticated-orcid":false,"given":"Samit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4908-6493","authenticated-orcid":false,"given":"Daniela","family":"Tirziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaide","family":"Chieffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-6967","authenticated-orcid":false,"given":"Giulio G.","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8002-7497","authenticated-orcid":false,"given":"Alexandra J.","family":"Lansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6512","key":"10.1016\/j.jscai.2023.100607_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(48)91585-2","article-title":"Salicylic acid for coronary thrombosis?","volume":"1","author":"Gibson","year":"1948","journal-title":"Lancet"},{"issue":"8607","key":"10.1016\/j.jscai.2023.100607_bib2","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jscai.2023.100607_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41569-018-0118-5","article-title":"Predictors of stent thrombosis and their implications for clinical practice","volume":"16","author":"Gori","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"6 Suppl B","key":"10.1016\/j.jscai.2023.100607_bib4","doi-asserted-by":"crossref","first-page":"155B","DOI":"10.1016\/0735-1097(91)90952-6","article-title":"Clinical experience with the Palmaz-Schatz coronary stent","volume":"17","author":"Schatz","year":"1991","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jscai.2023.100607_bib5","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/01.CIR.91.6.1676","article-title":"Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance","volume":"91","author":"Colombo","year":"1995","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jscai.2023.100607_bib6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A\u00a0randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jscai.2023.100607_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/CIRCULATIONAHA.109.921502","article-title":"Prasugrel","volume":"122","author":"Wiviott","year":"2010","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.jscai.2023.100607_bib8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jscai.2023.100607_bib9","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.jacc.2008.12.073","article-title":"Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice","volume":"53","author":"Doyle","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jscai.2023.100607_bib10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9038","key":"10.1016\/j.jscai.2023.100607_bib11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jscai.2023.100607_bib12","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0735-1097(99)00442-8","article-title":"Clopidogrel versus ticlopidine after intracoronary stent placement","volume":"34","author":"Berger","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jscai.2023.100607_bib13","first-page":"657","article-title":"Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation","volume":"18","author":"de Carvalho","year":"1999","journal-title":"Rev Port Cardiol"},{"issue":"6","key":"10.1016\/j.jscai.2023.100607_bib14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.CIR.101.6.590","article-title":"A\u00a0randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents","volume":"101","author":"M\u00fcller","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jscai.2023.100607_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc3001.093435","article-title":"Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population","volume":"104","author":"Taniuchi","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jscai.2023.100607_bib16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9281","key":"10.1016\/j.jscai.2023.100607_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jscai.2023.100607_bib18","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jscai.2023.100607_bib19","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jscai.2023.100607_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jscai.2023.100607_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.jscai.2023.100607_bib22","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.jscai.2023.100607_bib23","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jscai.2023.100607_bib24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib25","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Writing Committee","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jscai.2023.100607_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jscai.2023.100607_bib27","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"33","key":"10.1016\/j.jscai.2023.100607_bib28","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/eurheartj\/ehz917","article-title":"Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study","volume":"41","author":"Schnorbus","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jscai.2023.100607_bib29","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ahj.2008.06.004","article-title":"Pharmacology of emerging novel platelet inhibitors","volume":"156","author":"Angiolillo","year":"2008","journal-title":"Am Heart J"},{"issue":"14","key":"10.1016\/j.jscai.2023.100607_bib30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jscai.2023.100607_bib31","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jscai.2023.100607_bib32","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jscai.2023.100607_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pharmthera.2016.01.004","article-title":"Current status of data on cangrelor","volume":"159","author":"Qamar","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jscai.2023.100607_bib36","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jscai.2023.100607_bib37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A\u00a0clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.jscai.2023.100607_bib38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jscai.2023.100607_bib39","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jacc.2010.10.030","article-title":"Efficacy and safety of glycoprotein IIb\/IIIa inhibitors during elective coronary revascularization: A meta-analysis of randomized trials performed in the era of stents and thienopyridines","volume":"57","author":"Winchester","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamacardio.2016.4556","article-title":"Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb\/IIIa inhibitors: an exploratory analysis from the CHAMPION trials","volume":"2","author":"Vaduganathan","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jscai.2023.100607_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2021.04.013","article-title":"Cangrelor vs. glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention","volume":"238","author":"Yerasi","year":"2021","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.jscai.2023.100607_bib42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00005344-200304000-00011","article-title":"Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates","volume":"41","author":"Moser","year":"2003","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.jscai.2023.100607_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jscai.2023.100607_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002301","article-title":"Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines","volume":"8","author":"Capodanno","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"10.1016\/j.jscai.2023.100607_bib45","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jscai.2023.100607_bib46","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehn169","article-title":"Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8","volume":"29","author":"Widimsky","year":"2008","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jscai.2023.100607_bib47","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2010.01.067","volume":"56","author":"Di Sciascio","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jscai.2023.100607_bib48","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2012.50788","article-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"308","author":"Bellemain-Appaix","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jscai.2023.100607_bib49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00392-011-0393-1","article-title":"Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial","volume":"101","author":"Zeymer","year":"2012","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"10.1016\/j.jscai.2023.100607_bib50","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jscai.2023.100607_bib51","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"van Montalescot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.jscai.2023.100607_bib52","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of oral P2Y12 inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome","volume":"76","author":"Tarantini","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jscai.2023.100607_bib54","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O\u2019gara","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jscai.2023.100607_bib55","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ehjcvp\/pvab045","article-title":"Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground","volume":"7","author":"De Luca","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"13","key":"10.1016\/j.jscai.2023.100607_bib56","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jscai.2023.100607_bib57","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A\u00a0prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cpt.878","article-title":"Clopidogrel in critically ill patients","volume":"103","author":"Schoergenhofer","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jscai.2023.100607_bib59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"issue":"11","key":"10.1016\/j.jscai.2023.100607_bib60","article-title":"Cangrelor induces more potent platelet inhibition without increasing bleeding in resuscitated patients","volume":"7","author":"Pr\u00fcller","year":"2018","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ehjcvp\/pvaa009","volume":"7","author":"Gorog","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"19","key":"10.1016\/j.jscai.2023.100607_bib62","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10117","key":"10.1016\/j.jscai.2023.100607_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"issue":"10293","key":"10.1016\/j.jscai.2023.100607_bib64","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jscai.2023.100607_bib65","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM Extended Study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jscai.2023.100607_bib66","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.jscai.2023.100607_bib67","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jscai.2023.100607_bib68","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: A pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"10115","key":"10.1016\/j.jscai.2023.100607_bib69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jscai.2023.100607_bib70","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009565","article-title":"One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients","volume":"13","author":"Kandzari","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"13","key":"10.1016\/j.jscai.2023.100607_bib71","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jscai.2023.100607_bib72","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"18","key":"10.1016\/j.jscai.2023.100607_bib73","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jscai.2023.100607_bib74","article-title":"One-month dual antiplatelet therapy after bioresorbable polymer everolimus-eluting stents in high bleeding risk patients","volume":"11","author":"Pivato","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jscai.2023.100607_bib75","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008603","article-title":"Global approach to high bleeding risk patients with polymer-free drug-coated coronary stents: the LF II study","volume":"13","author":"Krucoff","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"33","key":"10.1016\/j.jscai.2023.100607_bib76","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","article-title":"Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a Master DAPT trial sub-analysis","volume":"43","author":"Valgimigli","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jscai.2023.100607_bib77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.jscai.2023.100607_bib78","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the Academic Research Consortium high bleeding risk definition in contemporary PCI patients","volume":"75","author":"Cao","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jscai.2023.100607_bib79","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jscai.2023.100607_bib80","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"issue":"25","key":"10.1016\/j.jscai.2023.100607_bib81","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9872","key":"10.1016\/j.jscai.2023.100607_bib82","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jscai.2023.100607_bib83","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jscai.2023.100607_bib84","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10206","key":"10.1016\/j.jscai.2023.100607_bib85","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"46","key":"10.1016\/j.jscai.2023.100607_bib86","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jscai.2023.100607_bib87","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: A North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jscai.2023.100607_bib88","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jscai.2023.100607_bib89","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jscai.2023.100607_bib90","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jscai.2023.100607_bib91","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.4244\/EIJY19M10_01","article-title":"Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?","volume":"15","author":"Tomaniak","year":"2020","journal-title":"EuroIntervention"},{"issue":"11","key":"10.1016\/j.jscai.2023.100607_bib92","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"16","key":"10.1016\/j.jscai.2023.100607_bib93","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"10151","key":"10.1016\/j.jscai.2023.100607_bib94","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jscai.2023.100607_bib95","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jscai.2023.100607_bib96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"24","key":"10.1016\/j.jscai.2023.100607_bib97","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.jscai.2023.100607_bib98","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.jscai.2023.100607_bib99","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"10055","key":"10.1016\/j.jscai.2023.100607_bib100","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (Antarctic): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"issue":"41","key":"10.1016\/j.jscai.2023.100607_bib101","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"issue":"10104","key":"10.1016\/j.jscai.2023.100607_bib102","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jscai.2023.100607_bib103","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A\u00a0genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10257","key":"10.1016\/j.jscai.2023.100607_bib104","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"issue":"10308","key":"10.1016\/j.jscai.2023.100607_bib105","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jscai.2023.100607_bib106","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jscai.2023.100607_bib107","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","article-title":"Effect of CYP2C19\u22172 and \u22173 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin","volume":"4","author":"Jeong","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"9892","key":"10.1016\/j.jscai.2023.100607_bib108","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.jscai.2023.100607_bib109","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jscai.2023.100607_bib110","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"10283","key":"10.1016\/j.jscai.2023.100607_bib111","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jscai.2023.100607_bib112","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.jscai.2023.100607_bib113","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jscai.2023.100607_bib114","article-title":"Cangrelor: clinical data, contemporary use, and future perspectives","volume":"10","author":"De Luca","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"14","key":"10.1016\/j.jscai.2023.100607_bib115","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"}],"container-title":["Journal of the Society for Cardiovascular Angiography & Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930323000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772930323000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:33:33Z","timestamp":1757424813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772930323000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2772930323000340"],"URL":"https:\/\/doi.org\/10.1016\/j.jscai.2023.100607","relation":{},"ISSN":["2772-9303"],"issn-type":[{"value":"2772-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Society for Cardiovascular Angiography & Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jscai.2023.100607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Society for Cardiovascular Angiography and Interventions Foundation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100607"}}